Related Experiment Videos
CDT6-expression can alter tumor sensitivity to chemotherapy.
Diane Bouïs1, Geke A P Hospers, Coby Meijer
1Department of Medical Oncology, University Hospital Groningen, P.O. Box 30001, 9700RB Groningen, The Netherlands.
Anticancer Research
|April 12, 2003
Summary
Cornea-derived transcript 6 (CDT6) enhances melanoma cell sensitivity to doxorubicin chemotherapy. This gene therapy approach may offer new strategies for cancer treatment by altering tumor drug responses.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Cornea-derived transcript 6 (CDT6), also known as AngX, exhibits known anti-tumor properties.
- Investigating novel therapeutic targets is crucial for improving cancer treatment outcomes.
Purpose of the Study:
- To evaluate the effect of CDT6 gene transfection on the sensitivity of murine melanoma cells (B16-F10) to cytostatic drugs.
- To elucidate the potential mechanisms underlying CDT6-mediated alterations in drug sensitivity.
Main Methods:
- Murine melanoma cell line B16-F10 was transfected with the CDT6 gene.
- The resulting B16-CDT6 cell line's sensitivity to various chemotherapeutic agents was compared to a control cell line (B16-CMV).
- Sensitivity was assessed using cytotoxic agents including doxorubicin, cisplatin, vincristine, etoposide, and taxol.
Main Results:
- The B16-CDT6 cell line demonstrated significantly increased sensitivity to doxorubicin.
- A trend towards decreased sensitivity to cisplatin was observed in the B16-CDT6 cells.
- No significant differences in sensitivity were found for vincristine, etoposide, or taxol between the B16-CDT6 and control cell lines.
Conclusions:
- CDT6 enhances doxorubicin sensitivity through a mechanism likely independent of efflux pumps (MRP, Pgp) or topoisomerase II.
- Gene therapy involving altered gene expression, such as with CDT6, can modulate tumor cell sensitivity to chemotherapy.
- These findings suggest potential for CDT6 in developing novel chemo-sensitizing cancer therapies.